Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
Armstrong
William B
WB
Department of Otolaryngology, Chao Family Comprehensive Cancer Center, University of California, Irvine, Orange, California 92868, USA.
Taylor
Thomas H
TH
Meyskens
Frank L
FL
D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis*; D017322:Clinical Trials, Phase II as Topic; D015195:Drug Design; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000378:metabolism / Q000517:prevention & control*; D011230:Precancerous Conditions / Q000378:metabolism / Q000517:prevention & control*; D011237:Predictive Value of Tests; D015203:Reproducibility of Results; D012307:Risk Factors
D016588:Anticarcinogenic Agents; D014408:Biomarkers, Tumor